Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.52 |
| ▸ | METAP1 | P53582 | 2/20 | 0.52 |
| ▸ | ACP3 | P15309 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28926750 | 0.84 | ACP3 (0.61) | METAP2METAP1ACP3EPHX2KMT2A | |
| SCHEMBL7809649 | 0.83 | ABCB1 (0.54) | ACP3CYP2C19ABCB1 | |
| SCHEMBL10616435 | 0.81 | SIGMAR1 (0.43) | METAP2METAP1ACP3ALDH1A1CYP1A2 | |
| SCHEMBL27991615 | 0.80 | CYP2C19 (0.48) | METAP2METAP1ACP3KMT2AALDH1A1 | |
| SCHEMBL7964583 | 0.79 | METAP2 (0.52) | METAP2METAP1ACP3EPHX2KMT2A | |
| SCHEMBL3741224 | 0.79 | METAP2 (0.46) | METAP2METAP1ACP3EPHX2KMT2A | |
| SCHEMBL25951940 | 0.79 | METAP2 (0.52) | METAP2METAP1ACP3EPHX2KMT2A | |
| SCHEMBL3923362 | 0.79 | CYP1A2 (0.47) | METAP2METAP1ACP3KMT2AALDH1A1 | |
| SCHEMBL3923359 | 0.79 | CYP1A2 (0.47) | METAP2METAP1ACP3KMT2AALDH1A1 | |
| SCHEMBL15171136 | 0.79 | ALDH1A1 (0.47) | METAP2METAP1ACP3KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023149553-A1 | METHOD FOR IMPROVING HARDNESS OF FIRED PRODUCT | 日産化学株式会社 | 2023-08-10 | — | — | WO | disclosed |
| US-20160248020-A1 | COMPOSITIONS CONTAINING FLUORENE SUBSTITUTED TRIAZINE DERIVED COMPOUNDS, AND ELECTRONIC DEVICES CONTAINING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-08-25 | — | — | US | disclosed |
| WO-2015073343-A1 | COMPOSITIONS CONTAINING FLUORENE SUBSTITUTED TRIAZINE DERIVED COMPOUNDS, AND ELECTRONIC DEVICES CONTAINING THE SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160248020-A1 | COMPOSITIONS CONTAINING FLUORENE SUBSTITUTED TRIAZINE DERIVED COMPOUNDS, AND ELECTRONIC DEVICES CONTAINING THE SAME | KCNA1, KCNC1, KCNA5 | METAP2 3231/4885METAP1 3036/4885ACP3 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.